abstract |
The invention relates to the field of 20S and/or 26S and 20S proteasome activation and modulation and to identify compounds which activate 20S and/or 26S proteasome in live cells and a method of treating neurodegenerative diseases/disorders and diseases characterized by protein aggregation and/or protein deposition, autoimmune diseases, infection diseases, and inflammation, by activation and modulation of the 20S and/or 26S proteasome. |